Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors

Hematology/Oncology Clinics of North America

Volumn 30, Issue 1, 2016, Pages 163-177

  Narayanan, Sujata ^a   Kunz, Pamela L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoid syndrome; Neuroendocrine tumors; Peptide receptor radionuclide therapy; Somatostatin analogues; Somatostatin receptors

Indexed keywords

ANGIOPEPTIN; LUTETIUM 177; OCTREOTIDE; PLACEBO; SEROTONIN; SEROTONIN DERIVATIVE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; YTTRIUM 90; SOMATOSTATIN;

ABDOMINAL CRAMP; ADVANCED CANCER; ANTIPROLIFERATIVE ACTIVITY; BILIARY TRACT DISEASE; BRONCHOSPASM; CANCER CONTROL; CARCINOID SYNDROME; CHOLELITHIASIS; CLINICAL FEATURE; DIARRHEA; EDEMA; FLATULENCE; FLUSHING; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPOTENSION; ISOTOPE LABELING; NAUSEA; NEUROENDOCRINE TUMOR; PATIENT MONITORING; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOISOTOPE THERAPY; REVIEW; STEATORRHEA; SYMPTOM; TELANGIECTASIA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; METABOLISM; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMORS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TRENDS;

DISEASE-FREE SURVIVAL; HUMANS; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84955127163     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2015.09.008     Document Type: Review

References (65)

1. Lawrence B., Gustafsson B.I., Chan A., et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011, 40(1):1-18. vii.
2. Yao J.C., Hassan M., Phan A., et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26(18):3063-3072.
3. Garcia-Carbonero R., Capdevila J., Crespo-Herrero G., et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010, 21(9):1794-1803.
4. Mocellin S., Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol 2013, 24(12):3040-3044.
5. Marx S., Spiegel A.M., Skarulis M.C., et al. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 1998, 129(6):484-494.
6. Donis-Keller H., Dou S., Chi D., et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2(7):851-856.
7. Rindi G.A.R., Bosman F.T., Arnold R., et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. WHO classification of tumours of the digestive system 2010, 13. International Agency for Research on cancer (IARC), Lyon. 4th edition.
8. Kulke M.H., Mayer R.J. Carcinoid tumors. N Engl J Med 1999, 340(11):858-868.
9. Schnirer , Yao J.C., Ajani J.A. Carcinoid-a comprehensive review. Acta Oncol 2003, 42(7):672-692.
10. Oberg K., Knigge U., Kwekkeboom D., et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl 7):vii124-vii130.
11. Brazeau P., Vale W., Burgus R., et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973, 179(4068):77-79.
12. Lamberts S.W., van der Lely A.J., de Herder W.W., et al. Octreotide. N Engl J Med 1996, 334(4):246-254.
13. Reichlin S. Secretion of somatostatin and its physiologic function. J Lab Clin Med 1987, 109(3):320-326.
14. Nilsson O., Kolby L., Wangberg B., et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 1998, 77(4):632-637.
15. Modlin I.M., Pavel M., Kidd M., et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010, 31(2):169-188.
16. Theodoropoulou M., Stalla G.K. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 2013, 34(3):228-252.
17. Reisine T., Bell G.I. Molecular biology of somatostatin receptors. Endocr Rev 1995, 16(4):427-442.
18. Benuck M., Marks N. Differences in the degradation of hypothalamic releasing factors by rat and human serum. Life Sci 1976, 19(8):1271-1276.
19. Reichlin S. Somatostatin. N Engl J Med 1983, 309(24):1495-1501.
20. Larsson L.I., Goltermann N., de Magistris L., et al. Somatostatin cell processes as pathways for paracrine secretion. Science 1979, 205(4413):1393-1395.
21. de Herder W.W., Hofland L.J., van der Lely A.J., et al. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003, 10(4):451-458.
22. Fjallskog M.L., Ludvigsen E., Stridsberg M., et al. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003, 20(1):59-67.
23. Thulin L., Samnegard H., Tyden G., et al. Efficacy of somatostatin in a patient with carcinoid syndrome. Lancet 1978, 2(8079):43.
24. Guillemin R. Peptides in the brain: the new endocrinology of the neuron. Science 1978, 202(4366):390-402.
25. Oberg K., Kvols L., Caplin M., et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004, 15(6):966-973.
26. Kidd M., Drozdov I., Joseph R., et al. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 2008, 113(4):690-700.
27. Bruns C., Lewis I., Briner U., et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002, 146(5):707-716.
28. Rubin J., Ajani J., Schirmer W., et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999, 17(2):600-606.
29. Bajetta E., Procopio G., Catena L., et al. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer 2006, 107(10):2474-2481.
30. Ruszniewski P., Ish-Shalom S., Wymenga M., et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004, 80(4):244-251.
31. Khan M.S., El-Khouly F., Davies P., et al. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther 2011, 34(2):235-242.
32. O'Toole D., Ducreux M., Bommelaer G., et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000, 88(4):770-776.
33. Vinik A., Wolin E., Audry H., et al. ELECT: a phase 3 study of efficacy and safety of lanreotide autoge/depot (LAN) treatment for carcinoid syndrome in patient with neuroendocrine tumors (NETs). J Clin Oncol 2014, 32(Suppl 3). [abstract: 268].
34. Hobday T, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. ASCO Annual Meeting June 1-5, Chicago, Il, abstract # 4504, 2007.
35. Schmid H.A., Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004, 80(Suppl 1):47-50.
36. Wolin E.M. A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs. J Clin Oncol 2013, 31(Suppl). [abstract: 4031].
37. Boyd A.E., DeFord L.L., Mares J.E., et al. Improving the success rate of gluteal intramuscular injections. Pancreas 2013, 42(5):878-882.
38. Strosberg J.R., Benson A.B., Huynh L., et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist 2014, 19(9):930-936.
39. Shen C., Shih Y.C., Xu Y., et al. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer 2014, 120(13):2039-2049.
40. Schally A.V. Oncological applications of somatostatin analogues. Cancer Res 1988, 48(24 Pt 1):6977-6985.
41. Susini C., Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol Dec 2006, 17(12):1733-1742.
42. Lawnicka H., Stepien H., Wyczolkowska J., et al. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 2000, 268(2):567-571.
43. Rinke A., Muller H.H., Schade-Brittinger C., et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009, 27(28):4656-4663.
44. Caplin M., Ruszniewski P., Pavel M., et al. Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: the CLARINET extension study. J Clin Oncol 2014, 32(Suppl 5s). [abstract: 4107].
45. Massimino K., Harrskog O., Pommier S., et al. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients. J Surg Oncol 2013, 107(8):842-846.
46. Angeletti S., Corleto V.D., Schillaci O., et al. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours. Ital J Gastroenterol Hepatol 1999, 31(1):23-27.
47. Haug A.R., Cindea-Drimus R., Auernhammer C.J., et al. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. Journal of nuclear medicine : official publication. J Nucl Med 2012, 53(11):1686-1692.
48. Arnold R., Chen Y.J., Costa F., et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009, 90(2):227-233.
49. Heppeler A., Froidevaux S., Eberle A.N., et al. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000, 7(9):971-994.
50. Waldherr C., Pless M., Maecke H.R., et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001, 12(7):941-945.
51. Waldherr C., Pless M., Maecke H.R., et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. Journal of nuclear medicine : official publication. J Nucl Med 2002, 43(5):610-616.
52. Paganelli G., Bodei L., Handkiewicz Junak D., et al. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002, 66(6):393-398.
53. Bodei L., Cremonesi M., Zoboli S., et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003, 30(2):207-216.
54. Bushnell D., O'Dorisio T., Menda Y., et al. Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. Journal of nuclear medicine : official publication. J Nucl Med 2003, 44(10):1556-1560.
55. Kwekkeboom D.J., de Herder W.W., Kam B.L., et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008, 26(13):2124-2130.
56. Wild D., Fani M., Fischer R., et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med 2014, 55(8):1248-1252.
57. Pavel M.E., Hainsworth J.D., Baudin E., et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011, 378(9808):2005-2012.
58. Kulke M. A randomized open-label phase II study of everolimus alone or in combination with pasireotide LAR in advanced, progressive pancreatic neuroendocrine tumors: COOPERATE-2 Trial. Presented at 12th Annual ENETS Conference, March 11-13, Barcelona, Spain, 2015.
59. Yao J. SWOG S0518: phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). J Clin Oncol 2015, 33(Suppl). [abstract: 4004].
60. Kulke M. Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). J Clin Oncol 2015, 33(Suppl). [abstract: 4005].
61. Hopfner M., Sutter A.P., Gerst B., et al. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer 2003, 89(9):1766-1775.
62. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247.
63. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10(1):1-10.
64. Agus D.B., Gordon M.S., Taylor C., et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005, 23(11):2534-2543.
65. Friess T., Scheuer W., Hasmann M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005, 11(14):5300-5309.